UnitedHealthcare · Semaglutide · US health-plan appeal rights

Semaglutide denied as not medically necessary by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Most insurers reverse a medical-necessity denial when the appeal cites the specific clinical guideline (NCCN, ADA, AACE, etc.) that supports the requested treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-05-04

At a glance

Why does UnitedHealthcare deny semaglutide for medical necessity?

Most often because BMI documentation, comorbidity framing, or step-therapy contraindication isn't satisfied verbatim in the chart — UHC reviewers don't infer.

What overturns a UHC semaglutide medical-necessity denial fastest?

Quoting the exact BMI, ICD-10 comorbidity code framed as weight-driven, dated 6-month diet/exercise program, and a chart-cited contraindication or trial of phentermine/topiramate or Contrave.

What federal regulation governs the appeal?

ERISA §503 and 29 CFR §2560.503-1 require a full review by a clinically qualified reviewer with the same training as the prescribing specialist.

How long do I have to appeal?

180 days for the internal appeal under ERISA §503(g); the clock starts from the date on the denial letter.

What's the single biggest mistake on these appeals?

Listing comorbidities as "co-existing" rather than "weight-driven" — UHC weights the linkage more than most plans, and unframed comorbidities at BMI 27-29 trigger automatic denial.

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

BMI >=30, OR BMI >=27 with at least one weight-related comorbidity (T2DM, hypertension, dyslipidemia, CVD, OSA). 6-month documented diet/exercise program. Step therapy: failed/contraindicated phentermine/topiramate or Contrave trial.

Source policy: GLP-1 Receptor Agonists for Weight Management

What works in the appeal

Step-therapy: Document contraindications to required agents - phentermine contraindicated in cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, MAOI use within 14 days (FDA prescribing information); phentermine/topiramate contraindicated in pregnancy, glaucoma, hyperthyroidism, MAOI use (FDA prescribing information); naltrexone/bupropion contraindicated in uncontrolled hypertension, seizure disorders, eating disorders, chronic opioid use, abrupt discontinuation of alcohol/benzodiazepines (FDA prescribing information). If prior trial completed: document inadequate response (weight loss <5% after 12 weeks per 2016 AACE/ACE obesity guidelines) or intolerance with specific adverse effects (e.g., tachycardia, insomnia, nausea, headache). Cite semaglutide 2.4mg FDA approval for chronic weight management in adults with obesity or overweight with weight-related comorbidity (June 2021). Reference STEP 1 trial showing semaglutide produced mean 14.9% body weight reduction vs 2.4% with placebo at 68 weeks (NEJM 2021;384:989-1002). Cite AMA recognition of obesity as a disease requiring treatment (2013) and 2016 AACE/ACE obesity algorithm supporting GLP-1 receptor agonists when lifestyle and first-line pharmacotherapy fail or are contraindicated. BMI threshold: Verify FDA indication (BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia). Supervised program: Document prior lifestyle intervention attempts including dietary counseling and increased physical activity per FDA indication requirements. Employer carve-out: Request plan documents confirming exclusion; appeal as medically necessary treatment for chronic disease; consider state parity laws if applicable.

The UnitedHealthcare angle on Semaglutide

UnitedHealthcare denies semaglutide for medical necessity most often when the BMI documentation is buried in the chart or when the comorbidity isn't explicitly framed as weight-driven. UHC reviewers — typically OptumRx pharmacists with structured criteria — don't infer; they look for each policy element satisfied verbatim in the documentation in front of them.

The appeal letter has to make every UHC criterion explicit and quoted from the chart:

BMI ≥30, or ≥27 with weight-related comorbidity — give the exact BMI from a recent visit (within 12 months), not a range.
Comorbidity framed as weight-driven — "obesity-associated hypertension responsive to weight loss" not "hypertension."
6-month documented diet/exercise program — give specific dates, the program name, and what was tried.
Step therapy or contraindication — either dates of phentermine/topiramate or Contrave trial with documented response, OR a chart-cited contraindication.
Side-effect contraindications — if the patient stopped phentermine due to anxiety, frame as contraindication, not "didn't tolerate."

The federal hook: medical-necessity denials are coverage determinations subject to ERISA §503 and 29 CFR §2560.503-1, requiring full review by a clinically qualified reviewer with the same training as the prescribing specialist.

OptumRx-specific procedural lever: cite the OptumRx GLP-1 PA Guideline version date in the appeal — older policy language sometimes still circulates.

Closing tactical tip: request peer-to-peer review with an endocrinologist before submitting the formal appeal — UHC's specialty-matched reviewers overturn at materially higher rates than generalists.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other insurers on Semaglutide

Other denial reasons for UnitedHealthcare Semaglutide

denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.